Court Grants IDEXX Laboratories' Motion for Preliminary Injunction Against Abaxis, Inc. and S.A. Scientific, Inc.Business/Technology Editors & Health/Medical Writers WESTBROOK, Maine--(BUSINESS WIRE)--Sept. 3, 2002 IDEXX Laboratories, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : IDXX) announced today that the United States District Court for the District of Maine The U.S. District Court for the District of Maine is the U.S. district court for the state of Maine. The District of Maine was one of the original thirteen district courts established by the Judiciary Act of 1789, even though Maine was not a separate state from Massachusetts until has issued an order granting its motion for preliminary injunction A temporary order made by a court at the request of one party that prevents the other party from pursuing a particular course of conduct until the conclusion of a trial on the merits. A preliminary injunction is regarded as extraordinary relief. against Abaxis, Inc. and S.A. Scientific, Inc. In a suit filed by IDEXX in March 2002, IDEXX claimed that canine heartworm heartworm Species (Dirofilaria immitis) of filarial worm that parasitizes mammals, especially dogs. Up to 500 adult heartworms, which can grow to 6–12 in. (15–30 cm) long, live in the dog's heart, and the microfilariae (embryonic larvae) pass into the blood. tests manufactured by S.A. Scientific and resold by Abaxis under the VetScan(R) name infringe certain IDEXX patents relating to the treatment of a blood sample prior to testing. IDEXX expects the preliminary injunction to be entered within the next few days. A trial on IDEXX's claims in which IDEXX will seek a permanent injunction permanent injunction n. a final order of a court that a person or entity refrain from certain activities permanently or take certain actions (usually to correct a nuisance) until completed. and damages is currently scheduled for December 2002. IDEXX Laboratories, Inc. is a worldwide leader in the development and commercialization of innovative, technology-based products and services for animal health. The Company's largest business is focused on companion animal health, combining biotechnology, medical device technology and information technology to aid veterinarians in providing better medicine while building successful practices. IDEXX Laboratories is also focused on employing innovative technologies to monitor production animal health and the safety and quality of drinking water drinking water supply of water available to animals for drinking supplied via nipples, in troughs, dams, ponds and larger natural water sources; an insufficient supply leads to dehydration; it can be the source of infection, e.g. leptospirosis, salmonellosis, or of poisoning, e.g. and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 2,100 people and offers products to customers in more than 50 countries. This press release contains forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, those that are discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2001, and in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2002, in the sections captioned "Management's Discussion and Analysis Management's discussion and analysis (MD&A) A report from management to shareholders that accompanies the firm's financial statements in the annual report. It explains the period's financial results and enables management to discuss topics that may not be apparent in the financial of Financial Condition and Results of Operations." |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion